Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Abstract

These findings define a genetic basis for benefit from CTLA-4 blockade in melanoma and provide a rationale for examining exomes of patients for whom anti-CTLA-4 agents are being considered. (Funded by the Frederick Adler Fund and others.).

Keywords

IpilimumabTremelimumabCTLA-4MedicineBlockadeMelanomaExome sequencingImmune checkpointImmunotherapyExomeCancer immunotherapyImmunologyNivolumabOncologyCancer researchT cellInternal medicineImmune systemMutationBiologyGenetics

Affiliated Institutions

Related Publications

Cancer immunotherapy using checkpoint blockade

Antoni Ribas , Jedd D. Wolchok

The release of negative regulators of immune activation (immune checkpoints) that limit antitumor responses has resulted in unprecedented rates of long-lasting tumor responses i...

2018 Science 6236 citations

The biologic importance of tumor‐infiltrating lymphocytes

F. Stephen Hodi , Glenn Dranoff

Detailed pathologic analysis has delineated a close association between intratumoral CD 8 + cytotoxic T cells and favorable clinical outcomes in diverse cancers. Conversely, the...

2010 Journal of Cutaneous Pathology 55 citations

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

James Larkin , Vanna Chiarion‐Sileni , René González +28 more

BACKGROUND Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advance...

2019 New England Journal of Medicine 3500 citations

Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response

Peng Jiang , Shengqing Gu , Deng Pan +12 more

Cancer treatment by immune checkpoint blockade (ICB) can bring long-lasting clinical benefits, but only a fraction of patients respond to treatment. To predict ICB response, we ...

2018 Nature Medicine 5230 citations

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

Lionel Apétoh , François Ghiringhelli , Antoine Tesnière +11 more

Summary: For the last four decades, the treatment of cancer has relied on four treatment modalities, namely surgery, radiotherapy, cytotoxic chemotherapy, and hormonotherapy. Mo...

2007 Immunological Reviews 545 citations

Publication Info

Year: 2014
Type: article
Volume: 371
Issue: 23
Pages: 2189-2199
Citations: 4287
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

4287

OpenAlex

Cite This

APA Style

                            
                                
                                    Alexandra Snyder, 
                                
                                    Vladimir Makarov, 
                                
                                    Taha Merghoub
                                
                                et al.
                            
                            (2014). 
                            Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. 
                            New England Journal of Medicine
                            , 371
                            (23)
                            , 2189-2199.
                            https://doi.org/10.1056/nejmoa1406498
                        

Identifiers

DOI: 10.1056/nejmoa1406498